RegWardenFDA facility compliance records
Recall

Class II — Delfi Medical Innovations, Inc.

Recalling firmDELFI MEDICAL INNOVATIONS INC.
Registered facilityDELFI MEDICAL INNOVATIONS INC. (the firm's only registered facility)
ClassificationClass II
StatusTerminated
ReasonDelfi Medical Innovations Inc has discovered that tourniquets cuffs in certain lots of the VariFit Sterile Single Use Thigh Cuffs, Single Port, Single Bladder models may have been manufactured with an inadequate perimeter weld on the cuff. Once applied to a patients thigh and inflated to a pressure to occlude blood flow in the thigh distal to the cuff, after a period of time the cuff may leak to the extent that the tourniquet instrument supplying air pressure to the cuff may not be able to adequately control and regulate pressure in the cuff. This may result in some blood flow in the thigh distal to the cuff.
ProductDelfi Medical Innovations, VariFit Contour Cuffs, single use adult thigh cuff, single port, single bladder, REF 9-9300-003. Rx Only, Sterile
Quantity59 units
DistributionUS: Ohio OUS: Austrailia
Initiated2019-04-03
Classified2020-05-05
Terminated2022-07-22
Recall numberZ-1901-2020
InitiationVoluntary: Firm initiated

Source: U.S. FDA via openFDA (opens in a new tab) (device registration & enforcement). Data as of 2026-10-06. Verify this recall record at FDA → (opens in a new tab)

Cite this record

RegWarden. “Class II recall — Delfi Medical Innovations, Inc. (Z-1901-2020).” Compiled from U.S. FDA public records (openFDA; FDA Data Dashboard). Data as of 2026-10-06. https://regwarden.com/recall/84741/

Not open yet

Alerts for DELFI MEDICAL INNOVATIONS INC.

Watchlist alerts will email you when FDA publishes a new recall, inspection classification, or warning letter for a facility you follow. They aren't open to the public yet — leave your email and we'll tell you when they are.

Planned

Want a one-page facility brief?

A single-page summary of this facility's registration and recall history for diligence. Not selling it yet — register interest and we'll follow up.